The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand–Foot Skin Reaction

References

• Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001–1011. doi:10.1634/theoncologist.2008-013118779536
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2016;17:387–402. doi:10.1007/s40257-016-0197-127221667
   PubMed Web of Science ®Google Scholar
• Hulin A, Stocco J, Bouattour M. Clinical pharmacokinetics and pharmacodynamics of transarterial chemoembolization and targeted therapies in hepatocellular carcinoma. Clin Pharmacokinet. 2019;58:983–1014. doi:10.1007/s40262-019-00740-w31093928
   PubMed Web of Science ®Google Scholar
• Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet. 2013;381:303–312. doi:10.1016/S0140-6736(12)61900-X23177514
   PubMed Web of Science ®Google Scholar
• Abrahao ABK, Ko YJ, Berry S, Chan KKWA. Comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer. 2018;17:113–120. doi:10.1016/j.clcc.2017.10.01629174481
   PubMed Web of Science ®Google Scholar
• Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78:747–758. doi:10.1007/s40265-018-0903-929663291
   PubMed Web of Science ®Google Scholar
• Chen R, Chen QT, Dong YH. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17. Oncol Lett. 2019;17:5447–5452. doi:10.3892/ol.2019.1027031186764
   PubMed Web of Science ®Google Scholar
• Si X, Zhang L, Wang H, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018;122:32–37. doi:10.1016/j.lungcan.2018.05.01330032842
   PubMed Web of Science ®Google Scholar
• Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500. doi:10.1016/S1470-2045(05)70243-615992698
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Ishigami M, Ito T, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res. 2019;49(9):1054–1065. doi:10.1111/hepr.1335831033165
   PubMed Web of Science ®Google Scholar
• Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77:257–271. doi:10.1159/00025888019923864
   PubMed Web of Science ®Google Scholar
• Granito A, Marinelli S, Negrini G, et al. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol. 2016;9(2):240–249. doi:10.1177/1756283X15618129
   PubMed Web of Science ®Google Scholar
• Nonomiya Y, Yokokawa T, Kawakami K, et al. Regorafenib-induced hand-foot skin reaction is more severe on the feet than on the hands. Oncol Res. 2019;27:551–556. doi:10.3727/096504018X1529172758974029914591
   PubMed Web of Science ®Google Scholar
• Yoshino T, Komatsu Y, Yamada Y, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015;33(3):740–750. doi:10.1007/s10637-014-0154-x25213161
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47:176–186. doi:10.1080/0284186070176567518210295
   PubMed Web of Science ®Google Scholar
• Anderson RT, Keating KN, Doll HA, Camacho F. The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology. Oncologist. 2015;20:831–838. doi:10.1634/theoncologist.2014-021926084809
   PubMed Web of Science ®Google Scholar
• Wang E, Xia D, Bai W, et al. Hand-foot-skin reaction of grade >/= 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. Invest New Drugs. 2019;37:401–414. doi:10.1007/s10637-018-0640-730019101
   PubMed Web of Science ®Google Scholar
• Moreno RA. [Curettage and gingivectomy in periodontal therapy. Histological clinical tests]. Rev Fed Odontol Colomb. 1974;22:83–88.4530428
   PubMedGoogle Scholar
• Fukuoka S, Shitara K, Noguchi M, et al. Prophylactic use of oral dexamethasone to alleviate fatigue during regorafenib treatment for patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2017;16:e39–e44. doi:10.1016/j.clcc.2016.07.01227780748
   PubMed Web of Science ®Google Scholar
• Su C, Wang Q, Zhang H, et al. Si-Miao-Yong-An Decoction protects against cardiac hypertrophy and dysfunction by inhibiting platelet aggregation and activation. Front Pharmacol. 2019;10:990. doi:10.3389/fphar.2019.0099031619988
   PubMed Web of Science ®Google Scholar
• Ren Y, Chen X, Li P, et al. Si-Miao-Yong-An decoction ameliorates cardiac function through restoring the equilibrium of SOD and NOX2 in heart failure mice. Pharmacol Res. 2019;146:104318. doi:10.1016/j.phrs.2019.10431831228552
   PubMed Web of Science ®Google Scholar
• Wang L, Wang N, Tan HY, Zhang Y, Feng Y. Protective effect of a Chinese Medicine formula He-Ying-Qing-Re Formula on diabetic retinopathy. J Ethnopharmacol. 2015;169:295–304. doi:10.1016/j.jep.2015.04.03125929449
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu Y, Tan H-Y, et al. Neuroprotective effect of He-Ying-Qing-Re formula on retinal ganglion cell in diabetic retinopathy. J Ethnopharmacol. 2018;214:179–189. doi:10.1016/j.jep.2017.12.01829253613
   PubMed Web of Science ®Google Scholar
• Shi S, Liu Z, Xue Z, Chen X, Chu Y. A plasma metabonomics study on the therapeutic effects of the Si-miao-yong-an decoction in hyperlipidemic rats. J Ethnopharmacol. 2020;256:112780. doi:10.1016/j.jep.2020.11278032222575
   PubMed Web of Science ®Google Scholar
• Hsu YH, Shen WC, Wang CH, Lin YF, Chen SC. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy. Eur J Oncol Nurs. 2019;43:101670. doi:10.1016/j.ejon.2019.09.01131586645
   PubMed Web of Science ®Google Scholar
• Ai L, Xu Z, Yang B, He Q, Luo P. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol. 2019;12:1121–1127. doi:10.1080/17512433.2019.168912231679411
   PubMed Web of Science ®Google Scholar
• Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894–900. doi:10.1200/JCO.2013.52.965125667293
   PubMed Web of Science ®Google Scholar
• Naganuma A, Hoshino T, Ohno N, et al. β-hydroxy-β-methyl butyrate/L-arginine/L-glutamine supplementation for preventing hand–foot skin reaction in sorafenib for advanced hepatocellular carcinoma. In Vivo (Brooklyn). 2019;33:155–161. doi:10.21873/invivo.11452
   PubMed Web of Science ®Google Scholar
• Chen J, Yu B, Wu X, et al. Effect of modified Taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. J Tradit Chin Med. 2014;34:10–14. doi:10.1016/s0254-6272(14)60047-925102684
   PubMed Web of Science ®Google Scholar
• Tian A, Zhou A, Bi X, et al. Efficacy of topical compound danxiong granules for treatment of dermatologic toxicities induced by targeted anticancer therapy: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2017;2017:3970601. doi:10.1155/2017/397060128845183
   PubMed Web of Science ®Google Scholar
• Wang G, Jia L, Pei Y, et al. Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs: protocol for a prospective, randomized, controlled, double-blind, and monocentric clinical trial. Medicine (Baltimore. 2020;99(4):e18849. doi:10.1097/MD.000000000001884931977883
   PubMed Web of Science ®Google Scholar